Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8617381 | 0.87 | — | — | |
| SCHEMBL19320232 | 0.87 | PLA2G4A (0.35) | PLA2G4AALDH1A1 | |
| SCHEMBL19320233 | 0.81 | PLA2G4A (0.43) | PLA2G4AFFAR3 | |
| SCHEMBL19317197 | 0.81 | TDP1 (0.39) | TDP1 | |
| SCHEMBL4206545 | 0.79 | KDM4E (0.44) | TDP1PLA2G4AALDH1A1 | |
| SCHEMBL93369 | 0.78 | — | — | |
| SCHEMBL31412009 | 0.77 | KDM4E (0.42) | TDP1PLA2G4AALDH1A1 | |
| SCHEMBL27142599 | 0.75 | TDP1 (0.43) | TDP1FFAR3ALDH1A1 | |
| SCHEMBL29508894 | 0.75 | TDP1 (0.43) | TDP1FFAR3ALDH1A1 | |
| SCHEMBL11983873 | 0.75 | CYP2C19 (0.41) | TDP1PLA2G4AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253623-A1 | IRIDIUM COMPLEX PRODUCTION METHOD | TANAKA KIKINZOKU KOGYO K.K. (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170253623-A1 | IRIDIUM COMPLEX PRODUCTION METHOD | TANAKA KIKINZOKU KOGYO K.K. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-0580336-B1 | Process for preparing optically active 4-methyl-2-oxetanone | TAKASAGO PERFUMERY CO LTD (JP) | 1998-09-30 | — | — | EP | disclosed |
| US-5412109-A | Process for preparing optically active 4-methyl-2-oxetanone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1995-05-02 | — | — | US | disclosed |
| US-5306834-A | Catalytic hydrogenation of 4-methylene-2-oxetanone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-04-26 | — | — | US | disclosed |
| EP-0580336-A1 | Process for preparing optically active 4-methyl-2-oxetanone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-01-26 | — | — | EP | disclosed |
| EP-0536105-A1 | Ruthenium(II)-binap diketonate complexes | MONSANTO COMPANY (US) | 1993-04-07 | — | — | EP | disclosed |
| US-5144050-A | Hydrogenation Catalysts | MONSANTO COMPANY (US) | 1992-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253623-A1 | IRIDIUM COMPLEX PRODUCTION METHOD | IPMK, TALDO1, BCKDK | TDP1 2789/4885PLA2G4A 3799/4885FFAR3 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.